Summaries of health policy coverage from major news organizations
GSK Withdraws Application Seeking Patent for Antiretroviral Drug Combivir in India
GlaxoSmithKline withdrew a patent application in India for its twice-daily antiretroviral Combivir, Bloomberg/Philadelphia Inquirer reports. Although GSK did not give details as to why the application was withdrawn, N.Y. Sanglikar, spokesperson for the company's India unit, said in a telephone interview that it was withdrawn "voluntarily." Medecins Sans Frontieres in March said that groups in the country opposed the application because the drug was not new. The drug also would become more expensive because pharmaceutical companies that produce generic versions would have had to pay a "reasonable royalty" to the company, according to MSF (Bloomberg/Philadelphia Inquirer, 8/22).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.